盐酸美法仑(Melphalan hydrochloride) - 药物靶点：DNA_在研适应症：葡萄膜黑色素瘤，急性淋巴细胞白血病，急性髓性白血病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

CE melphalan、CE-Melphalan HCl、Captisol-Enabled melphalan

+ [10]

靶点

DNA

作用机制

DNA抑制剂(DNA抑制剂)、DNA烷化剂

治疗领域

肿瘤免疫系统疾病心血管疾病+ [6]

在研适应症

葡萄膜黑色素瘤急性淋巴细胞白血病急性髓性白血病+ [9]

非在研适应症

免疫球蛋白轻链淀粉样变性系统性淀粉样变性

原研机构

Apotex, Inc.

在研机构

Adienne SRL

Delcath Systems, Inc.

Apotex, Inc.

+ [3]

非在研机构

Spectrum Pharmaceuticals, Inc.

最高研发阶段批准上市

首次获批日期

加拿大 (1963-09-26),

多发性骨髓瘤

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构

分子式C13H18Cl2N2O2

InChIKeySGDBTWWWUNNDEQ-LBPRGKRZSA-N

CAS号148-82-3

查看全部结构式(2)

关联

26

项与盐酸美法仑相关的临床试验

NCT05013437 / Withdrawn早期临床1期IIT

A Pilot Study to Assess Impact of Low Dose Melphalan on Disease Burden Measured by Next Generation Sequencing Before Autologous Hematopoietic Cell Transplant (AHCT) for Multiple Myeloma Patients

The purpose of this study is to see if Multiple Myeloma (MM) cells are sensitive to the chemotherapy used in transplant or not. The main chemotherapy agent utilized in stem cell transplant is melphalan. The study will utilize 1/10 of the dose used in transplant to study sensitivity of the tumor to melphalan. Melphalan is approved by the U.S. Food and Drug Administration (FDA) for transplant for MM patients.

开始日期2023-09-01

申办/合作机构

The Case Comprehensive Cancer Center

NCT05438394 / Recruiting临床1期IIT

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for Injection in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma

This study is an investigator-initiated clinical study to evaluate the safety and tolerability of melphalan hydrochloride for injection in patients with relapsed or relapsed refractory multiple myeloma. Using the "3 + 3" dose escalation principle, 3-6 subjects per dose were enrolled, depending on the dose limiting toxicity (DLT) observed in the first cycle of chemotherapy for each subject. After completing the 21-day assessment of the first cycle of chemotherapy, if there was no DLT, the study started for the next dose group.

开始日期2022-10-13

申办/合作机构

北京大学人民医院

[+1]

NCT04681417 / Recruiting临床2/3期IIT

Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018

This protocol includes 2 independent studies. Both studies are multicenter studies, evaluating different therapeutic approaches in two different populations of patients:
Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.
Study 2, a minimally invasive interventional study evaluating the results on visual function following reference treatment with intravenous (IV) chemotherapy in association with ophthalmologic or local ophthalmological treatment without IV chemotherapy.

开始日期2021-03-25

申办/合作机构

Institut Curie

[+1]

100 项与盐酸美法仑相关的临床结果

登录后查看更多信息

100 项与盐酸美法仑相关的转化医学

登录后查看更多信息

100 项与盐酸美法仑相关的专利（医药）

登录后查看更多信息

1,125

项与盐酸美法仑相关的文献（医药）

2024-06-01·Journal of NeuroInterventional Surgery

Efficacy of a prolonged stability melphalan formulation for intra-arterial treatment of retinoblastoma

Article

作者: Albuquerque, Felipe C ; Li, Amanda ; Abruzzo, Todd A ; Srinivasan, Visish M ; Luong, Hanna ; Jubran, Jubran H ; Feldman, Michael J ; Scherschinski, Lea ; Naik, Anant ; Ramasubramanian, Aparna

BackgroundMelphalan, which is poorly soluble at room temperature, is widely used for the treatment of retinoblastoma by selective ophthalmic artery infusion. Evomela, a propylene glycol-free formulation of melphalan with improved solubility and stability, has recently been used as an alternative.To compare the safety and efficacy of Evomela with standard-formulation melphalan (SFM) in the treatment of retinoblastoma by selective ophthalmic artery infusion.MethodsWe performed a retrospective case–control study of patients with retinoblastoma undergoing selective ophthalmic artery infusion with SFM or Evomela at a single institution. Cycle-specific percent tumor regression (CSPTR) was estimated by comparing photos obtained during pretreatment examination under anesthesia (EUA) with those obtained during post-treatment EUA 3–4 weeks later. CSPTR, ocular salvage rates, complication rates, operation times (unadjusted and adjusted for difficulty of ophthalmic artery catheterization), and intraprocedural dose expiration rates were compared between Evomela- and SFM-treated groups. Univariate and multivariate analyses were performed.ResultsNinety-seven operations (melphalan: 45; Evomela: 52) for 23 patients with 27 retinoblastomas were studied. The ocular salvage rate was 79% in the SFM-treated group and 69% in the Evomela-treated group. Multivariate regression controlling for tumor grade, patient age, and treatment history revealed no significant differences in ocular salvage rate, CSPTR, complication rates, or operation times. Although the dose expiration rate was higher for the SFM-treated group, the difference was not statistically significant. Notably, there were no ocular or cerebral ischemic complications.ConclusionEvomela has non-inferior safety and efficacy relative to SFM when used for the treatment of retinoblastoma by selective ophthalmic artery infusion.

2024-05-01·Food Chemistry

Identification and molecular binding mechanism of novel pancreatic lipase and cholesterol esterase inhibitory peptides from heat-treated adzuki bean protein hydrolysates

Article

作者: Gu, Jie ; Fan, Yimeng ; Zhao, Qingyu ; Zhu, Yiqing ; Shen, Qun ; Hao, Zhihui ; Zhao, Liangxing ; Xue, Yong ; Jiang, Yuanrong

Heat-treated adzuki bean protein hydrolysates exhibit lipid-reducing properties; however, few studies have reported pancreatic lipase (PL) and cholesterol esterase (CE) inhibitory effects and elucidated the underlying mechanisms. In this study, we accomplished the identification of antiobesity peptides through peptide sequencing, virtual screening, and in vitro experiments. Furthermore, the mechanisms were investigated via molecular docking. The findings reveal that the action of pepsin and pancreatin resulted in the transformation of intact adzuki bean protein into smaller peptide fragments. The < 3 kDa fraction exhibited a high proportion of hydrophobic amino acids and displayed superior inhibitory properties for both PL and CE. Five novel antiobesity peptides (LLGGLDSSLLPH, FDTGSSFYNKPAG, IWVGGSGMDM, YLQGFGKNIL, and IFNNDPNNHP) were identified as PL and CE inhibitors. Particularly, IFNNDPNNHP exhibited the most robust biological activity. These peptides exerted their inhibitory action on PL and CE by occupying catalytic or substrate-binding sites through hydrogen bonds, hydrophobic interactions, salt bridges, and π-π stacking.

2024-05-01·Ophthalmology and Therapy

Short-Term Efficacy of Ophthalmic Cyclosporine: A 0.1% Cationic Emulsion in Dry Eye Patients Assessed Under Controlled Environment

Article

作者: González-García, María J ; Pinto-Fraga, José ; Blanco-Vázquez, Marta ; Calonge, Margarita ; Valencia-Nieto, Laura ; Fernández, Itziar ; García-Vázquez, Carmen ; Enríquez-de-Salamanca, Amalia ; López-Miguel, Alberto

INTRODUCTIONTo evaluate the short-term efficacy of cyclosporine A (CsA)-0.1% cationic emulsion (CE) in patients with dry eye disease (DED) and mitigation of the inflammatory flares triggered by desiccating stress environments.METHODSA single-center non-randomized clinical trial was performed at a tertiary care setting. Twenty patients with DED treated with CsA 0.1% CE were exposed to a normal controlled environment (NCE) (23 °C, 50% relative humidity) and an adverse controlled environment (ACE) (23 °C, 10% relative humidity, 0.43 m/s localized airflow) during baseline and the 1- and 3-month visits. Patients underwent the following evaluations: conjunctival hyperemia and staining, corneal fluorescein staining (CFS) using the Oxford and Cornea and Contact Lens Research Unit (CCLRU) scale, meibomian gland (MG) secretion quality, Dry Eye Questionnaire-5, Symptom Assessment in Dry Eye (SANDE II), and Change in Dry Eye Symptoms Questionnaire. Multivariate models were adjusted for statistical analysis.RESULTSNineteen women and one man (mean age, 58.9 ± 12.3 years) completed the study. All symptom questionnaires, CFS, conjunctival hyperemia and staining, and MG secretion quality improved (p ≤ 0.003) with 1 month of treatment; improvements were maintained after 3 months (p ≤ 0.02), except for SANDE II (p ≥ 0.07). The CFS worsening (total CCLRU) after baseline ACE exposure (from 8.6 to 10.1) was higher, although not significant (p = 0.64), compared with 1 month (from 5.4 to 5.8) and 3 months (from 5.0 to 5.9) after treatment.CONCLUSIONTopical CsA-0.1% CE improved DED signs and symptoms after 1 month of treatment under controlled environmental conditions. Future studies should confirm the benefit of CsA-0.1% CE in desiccating stress environments.TRIAL REGISTRATIONClinicalTrials.gov identifier, NCT04492878.

143

项与盐酸美法仑相关的新闻（医药）

2024-10-30

·赛柏蓝

2024年国谈最后一天现场直击！石药、齐鲁、雅培等现身，涉降糖、肿瘤、抗菌、抗病毒药...

现场 | 颜色文字 | 凯西 2024年国家医保谈判终于来到了最后一天！有的企业谈判代表拖着行李箱出现在全国人大会议中心。赛柏蓝摄于现场北京相比于前几天有所降温（最高温度18度，最低温度6度）。 10月30日早上7点半左右，赛柏蓝现场观察发现，全国人大会议中心门外等待的谈判代表相较于前几天有所减少。随着工作人员的点名，石药集团欧意药业、江苏德源、杭州中美华东制药江东有限公司、齐鲁、江苏联环药业、正大天晴、河北天成药业、海南通用三洋药业、雅培贸易、西安力邦制药等企业的谈判代表陆续入场。目前谈判代表仍在进场中，进场的谈判代表人数在1-3人不等。据悉，今天上午谈判/竞价的产品包括抗排异药、降糖药、抗肿瘤药、抗菌药、抗病毒药等，如帕拉米韦注射液、注射用盐酸头孢吡肟/氯化钠注射液、注射用盐酸美法伦、二甲双胍恩格列净片等。随着今天谈判的顺利结束，2024年国家医保目录发布进入倒计时。根据国家医保局10月24日消息，预计11月份公布调整结果，新版药品目录将于2025年1月1日起实施。 END 内容沟通：郑瑶（13810174402）

一致性评价

2024-10-25

·BioSpace

Delcath Systems to Host Third Quarter 2024 Earnings Call

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2024, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Friday, November 8, 2024 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company’s website here . About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Delivery System (HDS). The HDS is used to surgically isolate the liver while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information , including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver. Contacts Investor Relations Contact: ICR Healthcare investorrelations@delcath.com

上市批准

2024-10-16

·米内网

【瞩目】15亿大品种，重庆药友制药获批了

精彩内容日前，国家药监局官网显示，重庆药友制药的甲磺酸仑伐替尼胶囊以仿制4类报产获批，视同过评。米内网数据显示，甲磺酸仑伐替尼胶囊在2023年中国三大终端六大市场（统计范围见文末）销售规模超过15亿元，2024年上半年同比增长1.65%。截至目前，重庆药友制药在抗肿瘤化药领域拥有超过20款产品生产批文，10款产品报产在审。来源：米内网项目进度数据库甲磺酸仑伐替尼是由日本卫材研制开发的一种口服多靶点酪氨酸激酶抑制剂，适用于既往未接受过全身系统治疗的不可切除的肝细胞癌患者的治疗。 2024年上半年中国三大终端六大市场内服抗肿瘤化药产品TOP10来源：米内网格局数据库甲磺酸仑伐替尼胶囊在2023年中国三大终端六大市场销售规模超过15亿元，2024年上半年同比增长1.65%，是内服抗肿瘤化药TOP8产品，卫材的市场份额最大。米内网数据显示，甲磺酸仑伐替尼胶囊有15家企业拥有生产批文，重庆药友制药、正大天晴药业集团、石药欧意药业等14家过评。10月12日，CDE官网显示，卫材申报新适应症上市申请获受理，在此之前，江苏康缘药业、敖东洮南药业等3家以仿制4类报产，目前均在审评审批中。今年以来重庆药友制药获批的抗肿瘤化药来源：米内网中国申报进度（MDE）数据库今年以来，重庆药友制药已有3款抗肿瘤化药产品获批上市，其中，甲磺酸仑伐替尼胶囊和奥沙利铂注射液均是10亿元级别的重磅品种。截至目前，公司在抗肿瘤化药领域拥有注射用培美曲塞二钠、哌柏西利胶囊等超过20款产品生产批文，瑞戈非尼片、注射用盐酸美法仑等10款产品报产在审。资料来源：国家药监局官网、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 ●温馨提示● 因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

上市批准一致性评价

100 项与盐酸美法仑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08173	盐酸美法仑	L01AA03	DB01042

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
急性淋巴细胞白血病	冰岛	Adienne SRL	2020-11-16
急性淋巴细胞白血病	列支敦士登	Adienne SRL	2020-11-16
急性淋巴细胞白血病	挪威	Adienne SRL	2020-11-16
急性淋巴细胞白血病	欧盟	Adienne SRL	2020-11-16
急性髓性白血病	冰岛	Adienne SRL	2020-11-16
急性髓性白血病	挪威	Adienne SRL	2020-11-16
急性髓性白血病	欧盟	Adienne SRL	2020-11-16
急性髓性白血病	列支敦士登	Adienne SRL	2020-11-16
乳腺腺癌	列支敦士登	Adienne SRL	2020-11-16
乳腺腺癌	欧盟	Adienne SRL	2020-11-16
乳腺腺癌	挪威	Adienne SRL	2020-11-16
乳腺腺癌	冰岛	Adienne SRL	2020-11-16
非霍奇金淋巴瘤	挪威	Adienne SRL	2020-11-16
非霍奇金淋巴瘤	冰岛	Adienne SRL	2020-11-16
非霍奇金淋巴瘤	列支敦士登	Adienne SRL	2020-11-16
非霍奇金淋巴瘤	欧盟	Adienne SRL	2020-11-16
卵巢癌	列支敦士登	Adienne SRL	2020-11-16
卵巢癌	冰岛	Adienne SRL	2020-11-16
卵巢癌	挪威	Adienne SRL	2020-11-16
多发性骨髓瘤	加拿大	-	1963-09-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
眼部黑色素瘤	申请上市	美国	Delcath Systems, Inc.	2023-03-27
黑色素瘤	临床3期	美国	Delcath Systems, Inc.	2022-06-10
浆细胞骨髓瘤难治	临床1期	中国	CASI Pharmaceuticals, Inc.	2022-10-13
免疫球蛋白轻链淀粉样变性	临床前	美国	Spectrum Pharmaceuticals, Inc.	2018-01-08
系统性淀粉样变性	临床前	美国	Spectrum Pharmaceuticals, Inc.	2018-01-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


BusinessWire 人工标引	N/A	葡萄膜黑色素瘤二线 \| 一线	30	HEPZATO KIT as first-line therapy	(餘鹹淵窪鏇簾窪獵廠淵) = 獵鹹觸夢淵繭網簾蓋憲獵壓夢鬱繭醖選築遞製 (窪網蓋餘艱鬱簾齋繭醖 ) 更多	积极	2024-08-27
				HEPZATO KIT as second-line therapy	(餘鹹淵窪鏇簾窪獵廠淵) = 膚範築憲淵廠廠積夢簾獵壓夢鬱繭醖選築遞製 (窪網蓋餘艱鬱簾齋繭醖 ) 更多
NCT03417284 (EHA2024) 人工标引	临床1/2期	多发性骨髓瘤一线	60	EVOMELA (short infusion)	(鬱鹽築襯顧淵鹹築窪壓) = 觸壓製鏇齋遞鏇糧鹹範製壓鑰夢獵膚鑰膚鏇廠 (壓鏇醖糧構鏇壓範廠觸 ) 更多	积极	2024-05-14
				EVOMELA (extend infusion)	(鬱鹽築襯顧淵鹹築窪壓) = 網鑰願蓋艱糧糧淵窪觸製壓鑰夢獵膚鑰膚鏇廠 (壓鏇醖糧構鏇壓範廠觸 ) 更多
Tandem Meetings ASTCT and CIBMTR2024 人工标引	N/A	多发性骨髓瘤一线	60	Evomela (Short Infusion (S-IV))	(艱顧製淵網選艱構餘淵) = 網齋積簾壓遞鬱遞艱鹽顧淵廠憲壓積艱廠憲遞 (築鬱蓋醖積構鏇遞積衊 ) 更多	积极	2024-02-01
				Evomela (Long Infusion (L-IV))	(艱顧製淵網選艱構餘淵) = 窪廠醖鑰製壓鏇鹹廠艱顧淵廠憲壓積艱廠憲遞 (築鬱蓋醖積構鏇遞積衊 ) 更多
ASH2023	临床1/2期	多发性骨髓瘤	60	Evomela (Short infusion)	(鏇簾鏇鹹窪鹹鑰鏇憲築): HR = 9.5 (95% CI, 1 ~ 91.2), P-Value = 0.022	-	2023-12-11
				Evomela (Extended infusion)
FDA 人工标引	N/A	多发性骨髓瘤	295	Melphalan hydrochloride (Oral)	(襯遞夢窪鏇蓋廠餘獵齋) = 糧窪鹽繭衊餘願顧築鑰觸鏇齋淵淵衊窪積獵窪 (繭選鹹壓襯繭壓壓衊夢 ) 更多	积极	2023-08-18
				Melphalan hydrochloride + Intravenous	(襯遞夢窪鏇蓋廠餘獵齋) = 鬱蓋觸醖糧憲範憲網築觸鏇齋淵淵衊窪積獵窪 (繭選鹹壓襯繭壓壓衊夢 ) 更多
NCT03128359 (CTgov)	临床2期	霍奇金淋巴瘤 \| 复发性浆细胞骨髓瘤 \| 慢性淋巴细胞白血病 \| 弥漫性大B细胞淋巴瘤 \| 急性白血病 \| 伴有骨髓发育不良相关变化的急性髓系白血病 \| 移植物抗宿主病 \| 继发性骨髓增生异常综合征 \| 滤泡性淋巴瘤 \| 套细胞淋巴瘤 \| 费城染色体阳性慢性粒细胞白血病 \| 浆细胞骨髓瘤难治 \| 边缘区B细胞淋巴瘤	38	Peripheral Blood Stem Cell Transplantation+Fludarabine Phosphate+CYCLOPHOSPHAMIDE+Tacrolimus+mycophenolate mofetil+Melphalan Hydrochloride (Regimen A (Fludarabine, Melphalan, PBSC HCT, GVHD Prophylaxis))	顧餘餘醖獵製窪獵鬱範(淵鹽膚積鬱遞艱醖鹽網) = 衊繭衊襯糧鏇顧製鏇觸膚衊積餘窪襯窪夢選願 (齋顧簾網繭範齋蓋鬱網, 鑰蓋廠壓廠艱簾繭鏇艱 ~ 顧繭鬱蓋膚鑰鹽膚醖衊) 更多	-	2023-06-09
				Peripheral Blood Stem Cell Transplantation+Fludarabine Phosphate+CYCLOPHOSPHAMIDE+Tacrolimus+mycophenolate mofetil (Regimen C (Fludarabine, TBI, PBSC HCT, GVHD Prophylaxis))	顧餘餘醖獵製窪獵鬱範(淵鹽膚積鬱遞艱醖鹽網) = 鑰夢淵鏇簾遞艱艱鬱憲膚衊積餘窪襯窪夢選願 (齋顧簾網繭範齋蓋鬱網, 鑰遞窪範築鏇衊蓋繭醖 ~ 醖鹽蓋製顧鏇鏇築選選) 更多
NCT02994784 (CTgov)	临床2期	免疫球蛋白轻链淀粉样变性 \| 系统性淀粉样变性	27	Propylene Glycol-Free Melphalan Hydrochloride	範鏇淵鬱積繭鑰窪憲憲(鏇簾鹽觸憲衊艱憲齋醖) = 憲壓憲築蓋簾構襯餘構鹹艱壓廠廠憲窪餘網廠 (襯顧築淵淵醖窪夢窪簾, 顧鏇廠積製網壓蓋齋網 ~ 齋鏇繭範衊鹹選鏇鹽餘) 更多	-	2023-05-24
P125 (EBMT2021)	N/A	巩固	59	High-dose melphalan	(製繭繭壓獵艱鑰鹹膚選) = 鑰窪夢繭憲選顧繭繭醖鏇窪憲繭鏇積餘鬱餘夢 (遞網廠糧夢製衊淵遞鏇, 59 ~ 112) 更多	积极	2021-03-14
Tandem Meetings ASTCT and CIBMTR2021	N/A	造血干细胞移植	-	Alkeran	(繭願壓顧淵膚鹽築鏇窪) = 鏇醖鏇艱憲獵繭鹽膚顧鬱顧廠鹽廠憲衊窪積窪 (醖構憲襯顧顧鬱鏇夢廠, 85.2 ~ 97.6) 更多	-	2021-03-01
				Evomela	(繭願壓顧淵膚鹽築鏇窪) = 簾廠願築鬱繭鑰襯鏇獵鬱顧廠鹽廠憲衊窪積窪 (醖構憲襯顧顧鬱鏇夢廠, 86.7 ~ 100) 更多
EBMT2020	N/A	淋巴瘤	87	Melphalan	(簾蓋觸獵構網築餘觸壓) = 餘鬱夢廠選憲餘構選壓餘膚選選範襯憲築齋壓 (夢淵鏇積膚窪範獵憲構, 3.8 ~ 18.8) 更多	-	2020-08-29
				Evomela	(醖醖憲繭廠遞積顧淵獵) = 觸襯遞廠膚鏇蓋顧觸願獵鬱憲鑰淵壓製糧獵廠 (廠憲選鏇夢糧齋觸選積, 76.5 ~ 100) 更多